Advertisement

Tumor Biology

, Volume 31, Issue 6, pp 673–679 | Cite as

The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer

  • Yoshihiro Minamiya
  • Masatomo Miura
  • Yudai Hinai
  • Hajime Saito
  • Manabu Ito
  • Kazuhiro Imai
  • Takashi Ono
  • Satoru Motoyama
  • Jun-ichi Ogawa
Research Article

Abstract

C-reactive protein (CRP) is one of the acute-phase proteins produced predominantly by hepatocytes in response to inflammation, and it has been widely reported that CRP genetic polymorphism is a risk factor for cardiovascular disease and ischemic stroke. In addition, we previously showed that the CRP 1846T/T genotype is related to lymph node metastasis in patients with esophageal cancer. In the present study, we investigated the correlation between CRP 1846C>T polymorphism and the clinicopathological characteristics of non-small cell lung cancer (NSCLC). The study participants were 146 Japanese patients who underwent curative surgery for NSCLC. DNA was extracted from tumor samples, and CRP1846C>T polymorphism was investigated using the polymerase chain reaction–restriction fragment length polymorphism method. We then correlated genotype with known clinicopathological factors. Five-year overall survival among patients with the CRP 1846T/T genotype was significantly lower than among those with the 1846C/C or C/T genotype (p = 0.002, p = 0.001; log-rank test). Multivariate Cox proportional hazard analysis revealed age, sex, pathological stage III, and 1846T/T (hazard ratio, 1.76; 95% confidence interval, 1.003–3.16; p = 0.049) to be independent factors affecting 5-year overall survival. These findings suggest the CRP 1846T/T genotype is an independent predictor of a poor prognosis in patients with NSCLC.

Keywords

Lung cancer C-reactive protein Polymorphism Prognosis 

Notes

Acknowledgment

This work was supported, in part, by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Science, Sports, and Technology of Japan.

References

  1. 1.
    Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Fleming JS, Beaugié CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol. 2006;247:4–21.CrossRefPubMedGoogle Scholar
  3. 3.
    Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J. 1997;11:457–65.PubMedGoogle Scholar
  4. 4.
    Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol. 2006;12:3746–50.PubMedGoogle Scholar
  6. 6.
    Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Koch A, Fohlin H, Sörenson S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol. 2009;4:326–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim DJ, et al. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer. 2009;63:106–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006;53:97–101.CrossRefPubMedGoogle Scholar
  10. 10.
    Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, et al. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res. 2007;27:3001–4.PubMedGoogle Scholar
  11. 11.
    Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005;77:64–77.CrossRefPubMedGoogle Scholar
  12. 12.
    Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med. 2005;83:440–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Hindorff LA, Rice KM, Lange LA, Diehr P, Halder I, Walston J, et al. Common variants in the CRP gene in relation to longevity and cause-specific mortality in older adults: the Cardiovascular Health Study. Atherosclerosis. 2008;197:922–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Hage FG, Szalai AJ. The role of C-reactive protein polymorphisms in inflammation and cardiovascular risk. Curr Atheroscler Rep. 2009;11:124–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Andersson J, Johansson L, Ladenvall P, Wiklund PG, Stegmayr B, Jern C, et al. C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study. Cerebrovasc Dis. 2009;27:544–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Motoyama S, Miura M, Hinai Y, Maruyama K, Usami S, Nakatsu T, et al. C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive protein levels after esophagectomy in patients with thoracic esophageal cancer. J Am Coll Surg. 2009;209:477–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Motoyama S, Miura M, Hinai Y, Maruyama K, Usami S, Saito H, et al. CRP genetic polymorphism is associated with lymph node metastasis in thoracic esophageal squamous cell cancer. Ann Surg Oncol. 2009;16:2479–85.CrossRefPubMedGoogle Scholar
  18. 18.
    Minamiya Y, Matsuzaki I, Sageshima M, Saito H, Taguchi K, Nakagawa T, et al. Expression of tissue factor mRNA and invasion of blood vessels by tumor cells in non-small cell lung cancer. Surg Today. 2004;34:1–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Sobin L, Wittekind C, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002. p. 99–103.Google Scholar
  20. 20.
    Thalmaier D, Dambacher J, Seiderer J, Konrad A, Schachinger V, Pfennig S, et al. The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1105–15.CrossRefPubMedGoogle Scholar
  21. 21.
    Su S, Lampert R, Zhao J, Bremner JD, Miller A, Snieder H, et al. Pleiotropy of C-reactive protein gene polymorphisms with C-reactive protein levels and heart rate variability in healthy male twins. Am J Cardiol. 2009;104:1748–54.CrossRefPubMedGoogle Scholar
  22. 22.
    Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001;47:444–50.PubMedGoogle Scholar
  23. 23.
    Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25:2097–116.CrossRefPubMedGoogle Scholar
  24. 24.
    Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y, Sugimachi K. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus—significance as a tumor marker. Cancer Lett. 2003;192:89–95.CrossRefPubMedGoogle Scholar
  25. 25.
    Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S, et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford). 2009;48:233–42.CrossRefGoogle Scholar
  26. 26.
    Bisoendial RJ, Birjmohun RS, Akdim F, van’t Veer C, Spek CA, Hartman D, et al. C-reactive protein elicits white blood cell activation in humans. Am J Med. 2009;122:582.e1–9.CrossRefGoogle Scholar
  27. 27.
    Khreiss T, József L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 2004;109:2016–22.CrossRefPubMedGoogle Scholar
  28. 28.
    Kolz M, Koenig W, Müller M, Andreani M, Greven S, Illig T, et al. DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: results from the AIRGENE study. Eur Heart J. 2008;29:1250–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Yoshihiro Minamiya
    • 1
  • Masatomo Miura
    • 2
  • Yudai Hinai
    • 2
  • Hajime Saito
    • 1
  • Manabu Ito
    • 1
  • Kazuhiro Imai
    • 1
  • Takashi Ono
    • 1
  • Satoru Motoyama
    • 1
  • Jun-ichi Ogawa
    • 1
  1. 1.Division of Thoracic Surgery, Department of SurgeryAkita University School of MedicineAkita CityJapan
  2. 2.Department of PharmacyAkita University HospitalAkita CityJapan

Personalised recommendations